What is the ROE (Return on Equity) of Oragenics this year?
The ROE of Oragenics this year is -6.52 undefined.
Oragenics ROE 2024
Oragenics ROE
-6.52
Ticker
OGEN
ISIN
US6840233026
WKN
A2JBK2
In 2024, Oragenics's return on equity (ROE) was -6.52, a 493.58% increase from the -1.1 ROE in the previous year.
Oragenics Aktienanalyse
What does Oragenics do?
Oragenics Inc is a biopharmaceutical company that focuses on the development of innovative technologies and products for the prevention and treatment of oral and systemic infectious diseases. The company was founded in 1996 as a private company and has since had an impressive track record in the development of diagnostic tools and therapeutics for various diseases in different fields. The company's business model is based on the identification and development of therapeutics that leverage innovative technologies such as bacterial toxins and probiotics. Their products aim to address both the causes of disease formation and the symptoms, contributing to improved patient well-being. Oragenics maintains partnerships and collaborations with other companies and research institutions to enhance its research and development efforts. The company is divided into multiple divisions, including the development of probiotic bacterial groups with specific immunotherapeutic functions, the development of biopharmaceutical products for the treatment of infectious diseases, and the development of diagnostics and screening tools for identifying oral infections. Oragenics has developed a range of products and technologies that can contribute to the improvement of oral and overall health, including a Streptococcus mutans detection system for dentists to identify and combat bacteria in the patient's mouth. One notable product is the TerraCoV2 COVID-19 vaccine, developed in collaboration with the National University of Singapore. Overall, Oragenics Inc has a remarkable track record in the development of innovative technologies and products, emphasizing product quality, rational manufacturing, and a wide range of medical devices. The company works closely with partners and collaborators to intensify its research and development efforts and provide innovative solutions and products. Oragenics ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Oragenics's Return on Equity (ROE)
Oragenics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Oragenics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Oragenics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Oragenics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Oragenics stock
How has the Return on Equity (ROE) of Oragenics developed compared to the previous year?
The ROE of Oragenics has increased by 493.58% increased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Oragenics?
A high ROE indicates that Oragenics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Oragenics?
A low ROE can indicate that Oragenics is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Oragenics affect the company?
A change in ROE (Return on Equity) of Oragenics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Oragenics?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Oragenics?
Some factors that can influence Oragenics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Oragenics pay?
Over the past 12 months, Oragenics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oragenics is expected to pay a dividend of 0 USD.
What is the dividend yield of Oragenics?
The current dividend yield of Oragenics is .
When does Oragenics pay dividends?
Oragenics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Oragenics?
Oragenics paid dividends every year for the past 0 years.
What is the dividend of Oragenics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Oragenics located?
Oragenics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Oragenics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Oragenics from 12/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/24/2024.
When did Oragenics pay the last dividend?
The last dividend was paid out on 12/24/2024.
What was the dividend of Oragenics in the year 2023?
In the year 2023, Oragenics distributed 0 USD as dividends.
In which currency does Oragenics pay out the dividend?
The dividends of Oragenics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Oragenics
Our stock analysis for Oragenics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oragenics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
